Gonzalez-Mancera Miguel Santiago

Gonzalez-Mancera Miguel Santiago

Auto-generated profile, based on publicly available information

Gonzalez-Mancera Miguel Santiago

Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center , Los Angeles, CA , US

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2019 in Turkish Journal of Hematology
Verified
Journal Article
Open access
MMMiguel S. Gonzalez - Mancera
Miguel S. Gonzalez - Mancera
NBNatalia I. Bolaños
Natalia I. Bolaños
MSManuel Salamanca
Manuel Salamanca
GOGuillermo A. Orjuela
Guillermo A. Orjuela
ARAyda N. Rodriguez
Ayda N. Rodriguez
JGJhon M Gonzalez
Jhon M Gonzalez
CD4+CD8+ double-positive T-cells (DPTs) have been classified as a separate T-cell subpopulation, with two main phenotypes: CD4high CD8low and CD4low CD8high. In recent years, the relevance of DPTs in the pathogenesis of infections, tumors, and autoimmune diseases has been recognized. Reference values among healthy individuals remain unknown. Therefore, the aim of this study is to provide a reference value for DPTs in peripheral blood from healthy donors in a blood bank in Bogotá, Colombia, and to determine the activation status using a surface marker. One hundred healthy donors were enrolled in the study. Peripheral blood cells were stained for CD3, CD4, CD8, and CD154 (CD40L), and cellular viability was assessed with 7-aminoactinomycin D and analyzed by flow cytometry. The median value for DPTs was 2.6% (interquartile range=1.70%-3.67%). Women had higher percentages of DPTs than men (3.3% vs. 2.1%). The subpopulation of CD4low CD8high showed higher expression of CD154 than the other T-cell subpopulations. DPT reference values were obtained from blood bank donors. A sex difference was found, and the CD4low CD8high subpopulation had the highest activation marker expression.

1 December 2021 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
MGMiguel S. Gonzalez‐Mancera
Miguel S. Gonzalez‐Mancera
SASaman S. Ahmadian
Saman S. Ahmadian
CGCarmen Gomez‐Fernandez
Carmen Gomez‐Fernandez
JVJaylou Velez‐Torres
Jaylou Velez‐Torres
MJMerce Jorda
Merce Jorda
MGMónica T. Garcia-Buitrago
Mónica T. Garcia-Buitrago

12 February 2024 in American Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
MGMiguel S Gonzalez-Mancera
Miguel S Gonzalez-Mancera
ASAndrew Siref
Andrew Siref
KKKambiz Kosari
Kambiz Kosari
NNNicholas Nissen
Nicholas Nissen
SGSrinivas Gaddam
Srinivas Gaddam
BLBrent K Larson
Brent K Larson
Adenocarcinomas of the biliary tract frequently present diagnostic challenges because of their histologic overlap with benign and preinvasive lesions. The molecular profiles of biliary adenocarcinomas vary by anatomical location. Variations in IDH1/2, common in intrahepatic cholangiocarcinoma, can lead to defective production of 5-hydroxymethylcytosine (5-hmC). Limited ancillary studies are available for biliary adenocarcinomas, and loss of 5-hmC staining could serve as a helpful ancillary diagnostic tool for biliary tract malignancies. We evaluated 93 cases—20 benign biliary lesions, 15 preinvasive biliary neoplasms, 46 invasive biliary carcinomas, and 12 pancreatic adenocarcinomas—for 5-hmC staining. Preoperative biopsies from 16 cases of biliary carcinoma were also stained. Sixteen nonneoplastic/reactive bile duct biopsies served as controls. Loss of 5-hmC was seen in 41 of 46 (89.1%) biliary malignancies vs 0 of 20 benign tumors (P < .001), for a sensitivity and specificity of 89.1% and 100%, respectively. Intrahepatic cholangiocarcinoma showed loss of 5-hmC in 11 of 13 (84.6%) cases, similar to the 30 of 33 (90.9%) cases in other biliary adenocarcinomas (P = .61). Similarly, 5-hmC loss was more frequent in distal bile duct adenocarcinomas than in pancreatic ductal adenocarcinomas, at 15 of 17 (88.2%) vs 4 of 12 (33.3%), respectively (P = .0045). There was no difference in the frequency of 5-hmC loss in patients that received neoadjuvant therapy vs those who did not (90.9% vs 88.6%, P > .99). 5-hmC immunohistochemistry in preoperative biopsies was concordant with the resection specimen in 81.3% (13/16) of cases. Loss of 5-hmC is not unique to intrahepatic cholangiocarcinoma among biliary carcinomas, but is a useful diagnostic marker differentiating malignancies of the biliary tree from benign mimics.

1 May 2020
Verified
Conference Paper
Open access
KSK.H.F.E.M. Santos
K.H.F.E.M. Santos
NHN. Hein
N. Hein
MZM. Zaw
M. Zaw
MGM.S. Gonzalez-Mancera
M.S. Gonzalez-Mancera
MMM. Murthi
M. Murthi
MMMehdi Mirsaeidi
Mehdi Mirsaeidi

27 January 2020 in Turkish Journal of Hematology
Verified
Journal Article
Open access
MGMiguel Santiago Gonzalez
Miguel Santiago Gonzalez
JGJohn Mario Gonzalez
John Mario Gonzalez

16 April 2020 in Turkish Journal of Hematology
Verified
Journal Article
Open access
GSGonzalez-Mancera Miguel Santiago
Gonzalez-Mancera Miguel Santiago
GMGonzalez John Mario
Gonzalez John Mario